TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33964942

Group type: EXPERIMENTAL
Intervention: Fractionated irradiation (5 × 2 Gy/week for 3-5 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blocking interferon-beta and/or -lambda
Number of subjects: 0

Group type: COMPARATOR
Intervention: Targeted inhibition of STING protein
Number of subjects: 0

Group type: COMPARATOR
Intervention: Knockout of STING expression
Number of subjects: 0
Study: 33965000

Group type: EXPERIMENTAL
Intervention: Lumacaftor-ivacaftor (100 mg-125 mg every 12 h for <14 kg, 150 mg-188 mg for ≥14 kg, 200 mg-250 mg for ≥6 years)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lumacaftor-ivacaftor
Number of subjects: 60
Study: 33965006

Group type: EXPERIMENTAL
Intervention: DAA treatment scale-up (12 weeks of sofosbuvir plus velpatasvir)
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: DAA treatment scale-up
Number of subjects: 1643
Study: 33965236

Group type: EXPERIMENTAL
Intervention: GCSF (Neupogen) at 5 μg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GCSF (Neupogen) at 10 μg/kg
Number of subjects: 16

Group type: COMPARATOR
Intervention: No GCSF (control group)
Number of subjects: 16
Study: 33965384

Group type: EXPERIMENTAL
Intervention: MARS1 immunofluorescence (IF) staining
Number of subjects: 240

Group type: COMPARATOR
Intervention: Conventional Pap staining
Number of subjects: 240
Study: 33965594

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study: 33966020

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: ACE-I/ARB
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Multitherapy
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Single antiplatelet therapy (SAPT)
Number of subjects: 964
Study: 33966087

Group type: EXPERIMENTAL
Intervention: Single-agent ibrutinib
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ibrutinib in combination with methotrexate with or without rituximab
Number of subjects: 53
Study: 33966128

Group type: EXPERIMENTAL
Intervention: Intravesical Bacillus Calmette-Guérin (BCG) combined with intravenous pembrolizumab
Number of subjects: 13
Study: 33966452

Group type: EXPERIMENTAL
Intervention: KBP-5074
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33966491

Group type: EXPERIMENTAL
Intervention: Andexanet alfa (bolus plus 2-hour infusion)
Number of subjects: 227
Study: 33966493

Group type: EXPERIMENTAL
Intervention: Capsaicin doses (33 to 165 μMol)
Number of subjects: 30
Study: 33966568

Group type: EXPERIMENTAL
Intervention: Opioid infusion with rapid once-daily weaning, especially rate reduction more than 50 µg as fentanyl equivalent per hour
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Opioid infusion with rapid once-daily weaning
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Opioid infusion
Number of subjects: 55

Group type: COMPARATOR
Intervention: Non-withdrawal group
Number of subjects: 55
Study: 33966635

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) with feature tracking analysis for RV global longitudinal strain assessment (RV GLS)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 18-FDG positron emission tomography (PET) analysis for RV glucose uptake
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of CMR and hemodynamic measurements
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (12 controls)
Number of subjects: 27
Study: 33966886

Group type: EXPERIMENTAL
Intervention: Cancer patients
Number of subjects: 262

Group type: COMPARATOR
Intervention: Non-cancer patients
Number of subjects: 262
Study: 33966954

Group type: EXPERIMENTAL
Intervention: Usual care phase of a multi-site quasi-experimental study
Number of subjects: 148
Study: 33967195

Group type: EXPERIMENTAL
Intervention: Bendamustine hydrochloride 120 mg/m2 infused intravenously on days 1 and 2 of each 21-day treatment cycle for at least six planned cycles (and up to eight cycles).
Number of subjects: 102
Study: 33967246

Group type: EXPERIMENTAL
Intervention: Minimally invasive image-guided left cochlear implantation (CI)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Traditional cochlear implantation
Number of subjects: 1
Study: 33967683

Group type: EXPERIMENTAL
Intervention: Intensive gait training with electromechanical assistance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive gait training without electromechanical assistance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33968064

Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (ART)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Late antiretroviral therapy (ART)
Number of subjects: 76
Study: 33968735

Group type: EXPERIMENTAL
Intervention: Patritumab Deruxtecan
Number of subjects: 0
Study: 33968845

Group type: EXPERIMENTAL
Intervention: Cardiovascular pharmacological support
Number of subjects: 0
Study: 33968949

Group type: EXPERIMENTAL
Intervention: Sputum Torque Teno Virus Load
Number of subjects: 0
Study: 33969012

Group type: EXPERIMENTAL
Intervention: Micro-CT-based quantification of extracted thrombus burden characteristics
Number of subjects: 0
Study: 33969423

Group type: EXPERIMENTAL
Intervention: Deep Sleepers
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Light Sleepers
Number of subjects: 125
Study: 33969456

Group type: EXPERIMENTAL
Intervention: Oral semaglutide (5-10 mg, multiple doses; 10 mg, single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 0
Study: 33969578

Group type: EXPERIMENTAL
Intervention: IM + 2 incisions
Number of subjects: 805

Group type: COMPARATOR
Intervention: SC + 2 incisions
Number of subjects: 805

Group type: COMPARATOR
Intervention: SC + 3 incisions
Number of subjects: 805

Group type: COMPARATOR
Intervention: IM + 3 incisions
Number of subjects: 805
Study: 33970027

Group type: EXPERIMENTAL
Intervention: 4K High-Definition System in Laparoscopic Gastrectomy
Number of subjects: 0
Study: 33970109

Group type: EXPERIMENTAL
Intervention: Personalized haptic feedback (vibrations) provided after 30 minutes of uninterrupted sitting
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Personalized haptic feedback provided between noon and 3 PM
Number of subjects: 26
Study: 33970392

Group type: EXPERIMENTAL
Intervention: Combination of HER2 and ER biomarkers, %HbT at the end of cycle 1 (EOC1), and %US (EOC1)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: %US (EOC1) and %HbT (EOC1) independent of HER2 and ER status
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: %US at EOC1 and %HbT (EOC3) independent of biomarker status
Number of subjects: 41
Study: 33970454

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salvage chemotherapy
Number of subjects: 0
Study: 33970687

Group type: EXPERIMENTAL
Intervention: Maintenance rucaparib
Number of subjects: 46
Study: 33970864

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory exercise plus Chinese herbal medicines
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory exercise only
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines only
Number of subjects: 172

Group type: COMPARATOR
Intervention: Waiting list group (receiving Chinese herbal medicines after 24 weeks)
Number of subjects: 172
Study: 33971009

Group type: EXPERIMENTAL
Intervention: Tdap vaccine (Boostrix; GSK) during pregnancy
Number of subjects: 0
Study: 33971036

Group type: EXPERIMENTAL
Intervention: Peak atrial longitudinal strain (PALS) measurement in patients with COPD
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: PALS as a predictor of atrial fibrillation (AF)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: PALS cutoff value for predicting AF
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Incidence of AF events in COPD patients
Number of subjects: 175
Study: 33971070

Group type: EXPERIMENTAL
Intervention: Viloxazine extended-release (viloxazine ER)
Number of subjects: 0
Study: 33971168

Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg subcutaneously every 4 weeks
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 140
Study: 33971185

Group type: EXPERIMENTAL
Intervention: Angiography-based decisions
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Invasive functional assessment
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Intravascular imaging
Number of subjects: 334

Group type: COMPARATOR
Intervention: Comparison to ISIS-1
Number of subjects: 334
Study: 33971650

Group type: EXPERIMENTAL
Intervention: Immunization records review and serological testing for tetanus
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Immunization records review and serological testing for varicella
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Immunization records review and serological testing for measles
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Vaccination status for various antigens
Number of subjects: 306
Study: 33971828

Group type: EXPERIMENTAL
Intervention: Arabin pessary
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Early insertion and close monitoring of the Arabin pessary
Number of subjects: 58
Study: 33971856

Group type: EXPERIMENTAL
Intervention: mepolizumab 100 mg administered subcutaneously
Number of subjects: 145
Study: 33971982

Group type: EXPERIMENTAL
Intervention: Patient Council involvement in the clinical study
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Patient Council's input to clinical protocol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Patient Council's role in dissemination of results and project advocacy
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Challenges faced by the Patient Council
Number of subjects: 5
Study: 33972002

Group type: EXPERIMENTAL
Intervention: Farm-to-Special Supplemental Nutrition Programme for Women, Infants and Children (WIC) intervention
Number of subjects: 297
Study: 33972083

Group type: EXPERIMENTAL
Intervention: IVF pregnancies
Number of subjects: 1347

Group type: COMPARATOR
Intervention: Spontaneous pregnancies
Number of subjects: 1347
Study: 33972315

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33972329

Group type: EXPERIMENTAL
Intervention: Geriatric fracture centres (GFCs)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Usual care centres (UCCs)
Number of subjects: 281
Study: 33972338

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 33972949

Group type: EXPERIMENTAL
Intervention: Lenzilumab (600 mg, n=261)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Placebo (n=259)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Lenzilumab (600 mg)
Number of subjects: 520
Study: 33973108

Group type: EXPERIMENTAL
Intervention: EQ-5D-5L utility index
Number of subjects: 453
Study: 33973232

Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Baseline alkaline phosphatase and baseline amylase
Number of subjects: 328
Study: 33973293

Group type: EXPERIMENTAL
Intervention: Subcutaneous envafolimab 0.01-10 mg/kg once weekly
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Subcutaneous envafolimab 300 mg once every 4 weeks
Number of subjects: 28
Study: 33973402

Group type: EXPERIMENTAL
Intervention: Baseline superficial medial femorotibial compartment (MFTC) T2 in progressor knees (adjusted mean 47.2 msec, 95% CI 46.5, 48.0)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Baseline superficial medial femorotibial compartment (MFTC) T2 in JSW progression only knees (adjusted mean 47.3 msec, 95% CI 46.3, 48.3)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Change in deep MFTC T2 between baseline and 12 months
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Baseline superficial medial cartilage T2
Number of subjects: 600
Study: 33973534

Group type: EXPERIMENTAL
Intervention: SPPB score at discharge
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: SPPB score 0-3 at discharge
Number of subjects: 119
Study: 33973550

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33973646

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 95
Study: 33973856

Group type: EXPERIMENTAL
Intervention: Dartmouth PATH Program (self-guided online intervention)
Number of subjects: 562
Study: 33973866

Group type: EXPERIMENTAL
Intervention: Video consultation
Number of subjects: 140

Group type: COMPARATOR
Intervention: Face-to-face consultation
Number of subjects: 140
Study: 33973868

Group type: EXPERIMENTAL
Intervention: Self-management support program for patients with LEP
Number of subjects: 137
Study: 33974038

Group type: EXPERIMENTAL
Intervention: Gene therapy (GT) using autologous bone marrow CD34+ cells transduced with MND-ADA gammaretroviral vector, infused after busulfan reduced-intensity conditioning.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gene therapy (GT)
Number of subjects: 10
Study: 33974216

Group type: EXPERIMENTAL
Intervention: Gliclazide modified release (MR)
Number of subjects: 1214
Study: 33974304

Group type: EXPERIMENTAL
Intervention: Cow's milk elimination diet (CME)
Number of subjects: 62
Study: 33974366

Group type: EXPERIMENTAL
Intervention: Autologous ex vivo lentiviral gene therapy
Number of subjects: 50
Study: 33974369

Group type: EXPERIMENTAL
Intervention: Bilateral implantation of a diffractive-refractive trifocal IOL
Number of subjects: 50
Study: 33974372

Group type: EXPERIMENTAL
Intervention: 6-minute walking test (6WT)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Timed Up and Go (TUG) test
Number of subjects: 49
Study: 33974419

Group type: EXPERIMENTAL
Intervention: Skepinone-based p38α MAP kinase inhibitors (methyl ester prodrugs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33974569

Group type: EXPERIMENTAL
Intervention: Higher levels of urinary EGF
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Higher levels of MCP-1
Number of subjects: 865
Study: 33974585

Group type: EXPERIMENTAL
Intervention: Matched Sibling Donor (MSD)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Matched Unrelated Donor (MUD)
Number of subjects: 45
Study: 33974707

Group type: EXPERIMENTAL
Intervention: HIV variants
Number of subjects: 2122

Group type: EXPERIMENTAL
Intervention: HLA alleles
Number of subjects: 2122

Group type: EXPERIMENTAL
Intervention: HIV variants and immunotypes
Number of subjects: 2122
Study: 33974994

Group type: EXPERIMENTAL
Intervention: Fecal immunochemical tests (FITs)
Number of subjects: 3600

Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 3600
Study: 33975540

Group type: EXPERIMENTAL
Intervention: CPAP adherence
Number of subjects: 132
Study: 33975557

Group type: EXPERIMENTAL
Intervention: Low vitamin D status (25(OH) D < 50 nmol/L) in rectal cancer patients
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Low vitamin D status in men
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Low vitamin D status in women
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: T4 disease presentation
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency
Number of subjects: 129
Study: 33975597

Group type: EXPERIMENTAL
Intervention: COVID-19 lockdown measures
Number of subjects: 2067
Study: 33975601

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 963

Group type: COMPARATOR
Intervention: Non-surgical treatment
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: ACME risk factors
Number of subjects: 963

Group type: COMPARATOR
Intervention: Tokyo Guidelines (TG) classification
Number of subjects: 963
Study: 33976135

Group type: EXPERIMENTAL
Intervention: Surgical resections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sputum samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genomic analysis of Mycobacterium tuberculosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of genetic diversity
Number of subjects: 0
Study: 33976538

Group type: EXPERIMENTAL
Intervention: Camrelizumab (3 mg/kg) combined with FOLFOX4 every two weeks
Number of subjects: 34
Study: 33976544

Group type: EXPERIMENTAL
Intervention: Visual assessment of CT
Number of subjects: 1221

Group type: COMPARATOR
Intervention: QCT assessment
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Visual assessments from both sets of radiologists
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Current smoking and female gender
Number of subjects: 1221
Study: 33977224

Group type: EXPERIMENTAL
Intervention: Primary care intervention to reverse frailty and enhance resilience through exercise and dietary protein education
Number of subjects: 0
Study: 33977387

Group type: EXPERIMENTAL
Intervention: Stage III Grade B generalized periodontitis (GP-B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Stage III Grade C generalized periodontitis (GP-C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (healthy individuals)
Number of subjects: 60
Study: 33977415

Group type: EXPERIMENTAL
Intervention: COVID-19 ARDS survivors
Number of subjects: 205

Group type: COMPARATOR
Intervention: Matched Italian population
Number of subjects: 205

Group type: COMPARATOR
Intervention: Matched Finnish population
Number of subjects: 205
Study: 33977686

Group type: EXPERIMENTAL
Intervention: Maximal ergospirometry
Number of subjects: 20
Study: 33978191

Group type: EXPERIMENTAL
Intervention: CUN-BAE index
Number of subjects: 54
Study: 33978519

Group type: EXPERIMENTAL
Intervention: Sleep Apnea, Daytime Sleepiness, Comorbidities, and Depression
Number of subjects: 198
Study: 33978593

Group type: EXPERIMENTAL
Intervention: iMedA (adaptive digital intervention delivered via a mobile app)
Number of subjects: 0
Study: 33978598

Group type: EXPERIMENTAL
Intervention: Virtual overdose response service (telephone-based)
Number of subjects: 15
Study: 33978600

Group type: EXPERIMENTAL
Intervention: TNF-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-17 inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JAK-inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuation of treatment after achieving remission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Effective suppression of inflammation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More sensitive measurements of radiographic progression
Number of subjects: 0
Study: 33979100

Group type: EXPERIMENTAL
Intervention: Trastuzumab with oxaliplatin and capecitabine followed by chemoradiotherapy
Number of subjects: 34
Study: 33979178

Group type: EXPERIMENTAL
Intervention: Lifileucel (autologous tumor-infiltrating lymphocyte therapy) with a nonmyeloablative lymphodepletion regimen and up to six doses of high-dose interleukin-2.
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lifileucel in primary refractory to anti-PD-1 or PD-L1 therapy subset.
Number of subjects: 66
Study: 33979183

Group type: EXPERIMENTAL
Intervention: Alternate Behavioral Interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33979314

Group type: EXPERIMENTAL
Intervention: miR-34a + miR-210
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: miR-122 + miR-210
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: miR-34a + miR-122
Number of subjects: 91
Study: 33979653

Group type: EXPERIMENTAL
Intervention: Intensity Modulated RT (IMRT)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Passive-Scattering Proton Therapy (PSPT)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Voxel-Based Analyses (VBAs)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: PICA and connectograms
Number of subjects: 178
Study: 33980224

Group type: EXPERIMENTAL
Intervention: PREVENT program (QI intervention)
Number of subjects: 35
Study: 33980232

Group type: EXPERIMENTAL
Intervention: Moderate sedation with oral administration of ketamine and midazolam
Number of subjects: 152

Group type: COMPARATOR
Intervention: Protective stabilization
Number of subjects: 152
Study: 33980287

Group type: EXPERIMENTAL
Intervention: Cerliponase alfa
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 8
Study: 33980522

Group type: EXPERIMENTAL
Intervention: Translocator protein (TSPO) positron emission tomography neuroimaging preoperatively and postoperatively
Number of subjects: 30
Study: 33980528

Group type: EXPERIMENTAL
Intervention: Neurological Pupil Index (NPi) assessment
Number of subjects: 420

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 420
Study: 33980575

Group type: EXPERIMENTAL
Intervention: Avasopasem manganese (AVA) given once before tumor irradiation and for 4 days after radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avasopasem manganese (AVA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose per fraction radiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conditional overexpression of catalase in tumors
Number of subjects: 0
Study: 33980605

Group type: EXPERIMENTAL
Intervention: Presence of microvascular disease (diabetic retinopathy, kidney disease, or CAN)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Advanced microvascular disease (moderate to severe albuminuria or eGFR <60 mL/min/1.73 m)
Number of subjects: 239
Study: 33980831

Group type: EXPERIMENTAL
Intervention: Isatuximab monotherapy
Number of subjects: 0
Study: 33980895

Group type: EXPERIMENTAL
Intervention: VR perceptual learning games (DartBoard and Halloween) with depth cue scaffolding conditions.
Number of subjects: 20
Study: 33980941

Group type: EXPERIMENTAL
Intervention: KRYPTOR assay
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: LIA assay
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: ELISA assay
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: KRYPTOR and LIA
Number of subjects: 88

Group type: COMPARATOR
Intervention: ELISA
Number of subjects: 88
Study: 33981160

Group type: EXPERIMENTAL
Intervention: Initial epidural SP-102 injection (10 mg dexamethasone sodium phosphate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeat epidural SP-102 injection (10 mg dexamethasone sodium phosphate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial and repeat SP-102 injections
Number of subjects: 0
Study: 33981279

Group type: EXPERIMENTAL
Intervention: BeatWalk application (individualized musical stimulation for gait rehabilitation)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: BeatWalk application
Number of subjects: 45
Study: 33981389

Group type: EXPERIMENTAL
Intervention: Probiotic chewing gum (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 40